Development and validation of a novel patient-reported outcome for microscopic colitis-Microscopic Colitis Score...

Area of Science:

• Gastroenterology
• Clinical Trials
• Patient-Reported Outcomes

Background:

• Microscopic colitis (MC) lacks a standardized disease severity index, hindering alignment with regulatory standards for new therapy approvals.
• Existing assessment gaps impede the use of patient-reported outcome measures (PROMs) crucial for FDA and EMA evaluations.
• This study addresses the need for validated tools to measure MC symptom severity and impact on quality of life.

Purpose of the Study:

• To validate the Microscopic Colitis Symptom Questionnaire (MCSQ) for assessing MC symptoms.
• To develop and validate a novel Microscopic Colitis Score (MCS) as a disease severity index.
• To ensure developed tools meet FDA and EMA standards for PROMs in clinical trials.

Main Methods:

• Prospective, multicenter study involving 131 patients with biopsy-confirmed microscopic colitis.
• Patients completed the MCSQ and health-related quality of life (HRQoL) assessments (IBDQ-32, SHS).
• Clustering analysis and factor analysis were used to develop and validate the MCS and MCSQ, respectively.

Main Results:

• The MCSQ demonstrated good internal consistency (Cronbach's alpha=0.88) and test-retest reliability (ICC=0.88).
• The novel Microscopic Colitis Score (MCS) ranged from 0-15 and strongly correlated with HRQoL measures (e.g., rp=-0.78 for IBDQ-32 total score).
• Receiver-operating characteristic curves showed MCS accurately identified disease states, including remission (AUC=0.85) and varying severity levels (AUCs 0.93-0.97).

Conclusions:

• The MCSQ and MCS are valid, reliable, and responsive tools for evaluating microscopic colitis.
• These instruments align with FDA and EMA standards for PROMs, reflecting diverse MC symptoms.
• The MCS offers a nuanced assessment of disease activity, promising for future therapeutic efficacy trials.